iBio initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of iBio (IBIO) with a Buy rating and $6 price target The company’s technology stack, which includes artificial intelligence-guided epitope steering and monoclonal antibody optimization, is designed to reduce development timelines and minimize the risk of late-stage failures, the analyst tells investors in a research note. The firm says iBio is advancing its partnered anti-myostatin program with AstralBio, targeting cardiometabolic diseases such as obesity.